Cure My Disease

Don't miss your cure!

 Log in / Sign up

NIH staff help unlock secrets of vaccine immunity in nose and blood

NCT ID NCT04794829

Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study follows 150 NIH staff members for about a year to see how their immune systems respond to flu and COVID-19 vaccines. Participants give monthly blood and nasal samples to measure antibodies in both the body and the nose. The goal is to understand how long immunity lasts and how it works in different parts of the body. No vaccines are given as part of the study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help design better vaccines that protect both the body and the nose against flu and COVID-19.
What could go wrong
This is an observational study, not testing a new treatment. Results may not apply to the general public, and the small size (150 people) limits conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Aug 2021

Finished

Jul 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

NIH staff may include employees and contractors, fellows, and volunteers.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. NIH staff members, at the time of enrollment. 2. Able to provide informed consent. 3. \>=18 years of age. 4. Planning to receive the current influenza season s vaccine and/or an FDA-authorized or approved SARS-CoV-2 vaccine. 5. Willing and able to undergo blood draws or home blood samplings and nasal sampling procedures. 6. Willing and able to undergo at least one blood draw and one nasal sampling prior to receiving vaccine. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Already received the current season s influenza vaccine and does not plan to receive an FDA-authorized or approved SARS CoV-2 vaccine. 2. Already received an FDA-authorized or approved SARS-CoV-2 vaccine and does not plan to receive the current season s influenza vaccine. 3. Not willing to receive the current influenza season's vaccine and not willing to receive an FDA-authorized or approved SARS-CoV-2 vaccine. 4. Any condition that, in the opinion of the investigator, contraindicates participation in this study. Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 Influenza

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.